Related Experiment Video
Updated: Jun 18, 2026
05:10
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
12.2K
Effective Use of ALK Inhibitors in EML4::ALK-Positive Lymphatic Malformations.
Beth Apsel Winger1,2, Christopher F Dowd3, Kristin A Shimano2
1Department of Clinical Pharmacy, UCSF, San Francisco, California, USA.
Pediatric Blood & Cancer
|November 12, 2024
Summary
ALK inhibitors show promise for treating lymphatic malformations (LMs) resistant to sirolimus. These targeted therapies offer new hope for patients with EML4::ALK-positive LMs, including rare conditions like Gorham Stout disease.
Area of Science:
- Oncology
- Genetics
- Vascular Biology
Background:
- Lymphatic malformations (LMs) are congenital vascular anomalies.
- Sirolimus is a common treatment, but some LMs are unresponsive.
- Genetic mutations, such as EML4::ALK fusions, can drive LM development.
Observation:
- Two patients with EML4::ALK-positive LMs were identified.
- One patient had Gorham Stout disease, a rare skeletal disorder with LM involvement.
- The other patient had a large genitourinary (GU) LM.
Findings:
- Both patients with EML4::ALK-positive LMs achieved successful treatment outcomes using ALK inhibitors.
- ALK inhibitors represent a novel therapeutic strategy for specific LM subtypes.
- This demonstrates the efficacy of genetically targeted therapies in managing complex LMs.
Implications:
- ALK inhibitors expand the therapeutic options for refractory LMs.
- Molecularly targeted therapies are becoming increasingly important for rare diseases.
- Further research into ALK-driven LMs may uncover more treatment avenues.
